Therapeutic Outcomes of ۱۷۷Lu-PSMA Targeted Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Single-Center Study
سال انتشار: 1402
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 148
فایل این مقاله در 7 صفحه با فرمت PDF قابل دریافت می باشد
- صدور گواهی نمایه سازی
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
JR_JNMB-11-1_004
تاریخ نمایه سازی: 25 دی 1401
چکیده مقاله:
Objective(s): This study aimed to evaluate the therapeutic outcomes of ۱۷۷Lutetium (۱۷۷Lu)-PSMA-۶۱۷ in metastatic castrate-resistant prostate cancer (mCRPC) patients, based on post-treatment imaging findings. Methods: All post-therapeutic scans were collected retrospectively from patients treated with ۱۰۰-۲۰۰ mCi ۱۷۷Lu-PSMA-۶۱۷ from March ۲۰۱۸ to December ۲۰۲۰ for mCRPC. Two independent readers interpreted the scans and visually categorized them into three strata: responsive, stable, and progressive. The responses were defined based on changes in the number of detected lesions, as well as the intensity of the hottest lesion. Data were registered, and the trend of changes was descriptively discussed. Results: Out of ۳۶ patients (aged ۶۷±۸.۸ years), ۲۳ underwent at least two treatment cycles. Nineteen patients (۸۲.۶%) had bone metastases, ۱۲ (۵۲.۲%) had nodal metastases, ۵ (۲۱.۷%) had liver metastases, and ۳ (۱۳.۰%) had lung metastases. Eleven patients (۴۷.۸%) were considered responsive in the post-therapeutic scans, two of which experienced complete eradication of the metastatic sites. Three patients (۱۳%) were categorized as progressive, and ۹ (۳۹.۱%) patients remained stable. Regarding mortality, nine patients died during the late follow-up (median of ۲۴ months). In the surviving population, ۶۵% reported no or mild pain in the final follow-up, based on a ۵-point scale pain assessment. Conclusion: The treatment of mCRPC patients with ۱۷۷Lu-PSMA-۶۱۷ may limit their disease progression and preserve their physical performance, which are important factors in their survival and quality of life.
کلیدواژه ها:
نویسندگان
Seyed Ali Mirshahvalad
Research Center for Nuclear Medicine, Dr. Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
Saeed Farzaneh Far
Valiasr Hospital, Tehran University of Medical Sciences
Mehrshad Abbasi
Department of Nuclear Medicine, Vali-Asr Hospital Tehran University of Medical Sciences, Tehran ۱۴۱۹۷۳۱۳۵۱, Iran
مراجع و منابع این مقاله:
لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :